Trial Watch: Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

Evidence stage: Later-Stage HumanRegulatory status: InvestigationalGuideline status: Not addressed

Important context

What changed: ClinicalTrials.gov lists Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation (NCT06956001) as a Phase 3 interventional cancer study. The registry status is Recruiting, with the record last updated 2026-08-13.

Study snapshot: Phase 3; Recruiting; planned enrollment 300. Conditions listed: EGFR, NSCLC (Advanced Non-small Cell Lung Cancer). A primary outcome listed by the registry is: Progression-free survival (PFS) assessed by the Independent Review Committee (BICR) according to RECIST v1.1..

This entry tracks verified trial-registry facts. Trial registration by itself does not show that an intervention is effective, safe for a particular person, FDA-approved for this use, or recommended by clinical guidelines.

What This Means

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

What This Doesn't Mean

A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.

Why It Matters

Phase 3 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.

Promise & Proof

Proof — strength of the evidence 4 / 5
  • Base score from evidence stage: Later-Stage Human.
Promise — potential significance if later evidence holds up 3 / 5
  • Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
  • The record includes substantive editorial reasoning about why this discovery matters.
  • Targets a cancer type with historically limited effective treatment options.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Participants age 18 Years and older with EGFR, NSCLC (Advanced Non-small Cell Lung Cancer) who meet the study-specific registry eligibility criteria. (Adults)

Eligibility is study-specific. Registry information does not determine whether any individual should enroll in or receive the intervention.

Full evidence details
Study design
Other / not applicable
Sample size
300
Primary outcome
Progression-free survival (PFS) assessed by the Independent Review Committee (BICR) according to RECIST v1.1.
Replication
Unknown

Funding & Conflicts

ClinicalTrials.gov lists the lead sponsor as Allist Pharmaceuticals, Inc.. Sponsorship is reported for transparency and does not establish efficacy.

Regulatory status by jurisdiction

Unspecified jurisdiction

Status
Investigational
Last verified
2026-08-14

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position
Not addressed
Last verified
2026-08-14

Primary evidence supporting this story

Why Should I Trust This?

  • 1 source at Tier 1 — Government/regulatory authority (FDA, NCI, NIH, ClinicalTrials.gov, CDC, and equivalent)
  • Correction/retraction status: No correction or retraction
  • Last reviewed: 2026-08-14

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

  1. Status change — Status changed from "In editorial review" to "Verified".
  2. Status change — Status changed from "Legacy / Unverified" to "In editorial review".

Last reviewed

Related discoveries

Trial Watch: Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

https://cancerdiscoveries.com/discoveries/trial-watch-firmonertinib-versus-platinum-based-chemotherapy-as-first-line-treatment-for-nsclc-with-egfr-pacc-or-egfr-l861q-mutation/

Evidence stage: Later-Stage Human

What This Means

ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.

What This Doesn't Mean

A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.

Why It Matters

Phase 3 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.

Important Limitations

  • Clinical-trial participation has study-specific eligibility criteria; registry listing does not mean a person qualifies or should enroll.

Primary sources

  • ClinicalTrials.gov — NCT06956001 — https://clinicaltrials.gov/study/NCT06956001 (NCT06956001)

Date verified: 2026-08-14

Correction status: No correction or retraction